Aprepitant for PONV Prophylaxis in Outpatient Plastic Surgery

Completed · Phase 4 · Has a placebo group

Conditions studied: Postoperative Nausea and Vomiting

In brief

Hypothesis: Aprepitant plus ondansetron is more effective than ondansetron plus placebo for prevention of postoperative emesis in patients at moderate-to-high risk for PONV for up to 48 hours after surgery. Specific Aim: To determine the incidence of PONV during the first 48 hours after surgery; in patients who have received aprepitant plus ondansetron versus ondansetron plus placebo for up to 48 hours after surgery.

Key facts

Study ID
NCT00659945
Run by
University of Pittsburgh
People needed
150
Starts
2008-06-01
Expected to finish
2010-06-01
Last updated by the study team
2013-02-06

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.